Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.45 |
| ▸ | PDE4A | P27815 | 7/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.38 |
| ▸ | REN | P00797 | 5/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2175768 | 1.00 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4DREN | |
| SCHEMBL2178941 | 1.00 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4DREN | |
| SCHEMBL1133570 | 1.00 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4DREN | |
| SCHEMBL1133256 | 1.00 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4DREN | |
| SCHEMBL1133185 | 0.88 | PDE4A (0.46) | PDE4BPDE4APDE4CPDE4DREN | |
| SCHEMBL1133221 | 0.88 | PDE4A (0.46) | PDE4BPDE4APDE4CPDE4DREN | |
| SCHEMBL3389298 | 0.87 | REN (0.40) | PDE4BPDE4APDE4CPDE4DREN | |
| SCHEMBL4955591 | 0.87 | REN (0.40) | PDE4BPDE4APDE4CPDE4DREN | |
| SCHEMBL4955261 | 0.87 | REN (0.40) | PDE4BPDE4APDE4CPDE4DREN | |
| SCHEMBL2175523 | 0.87 | REN (0.42) | PDE4BRENTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230665-A1 | SYNTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | MICKEL STUART JOHN | 2011-09-22 | — | — | US | disclosed |
| US-7973175-B2 | pyrrolidine chemical intermediates useful in the synthesis of drugs, especially enzyme inhibitors, such as Aliskiren | NOVARTIS AG (CH) | 2011-07-05 | — | — | US | disclosed |
| EP-2287153-A1 | Synthesis Of Renin Inhibitors Involving A Cycloaddition Reaction | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| EP-1931629-B1 | SYNTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | NOVARTIS AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-20080255369-A1 | Synthesis of Renin Inhibitors Involving a Cycloaddition Reaction | NOVARTIS AG (CH) | 2008-10-16 | — | — | US | disclosed |
| EP-1931629-A1 | SYTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | Novartis AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007039183-A1 | SYTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255369-A1 | Synthesis of Renin Inhibitors Involving a Cycloaddition Reaction | REN, AGTR1, AGTR2 | PDE4B 1472/4885PDE4A 1503/4885PDE4C 2387/4885 |
| US-20110230665-A1 | SYNTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | REN, AGTR1, AGTR2 | PDE4B 1472/4885PDE4A 1503/4885PDE4C 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.